Log in

NASDAQ:ARQL - ArQule Stock Price, Forecast & News

$20.00
0.00 (0.00 %)
(As of 01/17/2020 04:00 PM ET)
Add
Compare
Today's Range
$20.00
Now: $20.00▼
$20.00
50-Day Range
$9.11
MA: $17.93▼
$20.36
52-Week Range
$3.15
Now: $20.00▼
$20.45
VolumeN/A
Average Volume5.27 million shs
Market Capitalization$2.42 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.49
ArQule, Inc, a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ARQL
Previous Symbol
CUSIP04269E10
CIK1019695
Webhttp://www.arqule.com/
Phone781-994-0300

Debt

Debt-to-Equity Ratio0.08
Current Ratio8.27
Quick Ratio8.27

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$25.76 million
Price / Sales93.85
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.72 per share
Price / Book27.78

Profitability

EPS (Most Recent Fiscal Year)($0.16)
Net Income$-15,480,000.00
Net Margins-805.61%
Return on Equity-33.10%
Return on Assets-26.87%

Miscellaneous

Employees36
Outstanding Shares120,873,000
Market Cap$2.42 billion
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive ARQL News and Ratings via Email

Sign-up to receive the latest news and ratings for ARQL and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:ARQL Rates by TradingView

(Ad)


A devastating technical glitch could crush the next generation of wireless technology before it even launches. With trillions of dollars and millions of jobs at stake, one company with the "5G fix" could put as much as $234,770 in your pocket this year. But Wall Street vultures are circling... you'll need to move quickly or risk missing this $5 bargain.

ArQule (NASDAQ:ARQL) Frequently Asked Questions

What is ArQule's stock symbol?

ArQule trades on the NASDAQ under the ticker symbol "ARQL."

How were ArQule's earnings last quarter?

ArQule, Inc. (NASDAQ:ARQL) released its earnings results on Wednesday, October, 30th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.01. The biotechnology company had revenue of $0.21 million for the quarter, compared to analyst estimates of $1.20 million. ArQule had a negative return on equity of 33.10% and a negative net margin of 805.61%. During the same period last year, the business earned ($0.05) earnings per share. View ArQule's Earnings History.

When is ArQule's next earnings date?

ArQule is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for ArQule.

What price target have analysts set for ARQL?

9 equities research analysts have issued 1 year target prices for ArQule's stock. Their forecasts range from $12.00 to $20.00. On average, they expect ArQule's stock price to reach $17.50 in the next twelve months. This suggests that the stock has a possible downside of 12.5%. View Analyst Price Targets for ArQule.

What is the consensus analysts' recommendation for ArQule?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ArQule in the last year. There are currently 6 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ArQule.

What are Wall Street analysts saying about ArQule stock?

Here are some recent quotes from research analysts about ArQule stock:
  • 1. According to Zacks Investment Research, "ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Roche. " (10/31/2019)
  • 2. HC Wainwright analysts commented, "We are initiating coverage with a Buy rating and $13 price target. ArQule is a development stage biotech company that is developing four novel oral products, three for oncology indications and one for rare overgrowth diseases. Our price target is based on two of the drugs in the company’s pipeline, specifically ARQ 531 for B-cell malignancies and miransertib for rare tissue overgrowth diseases. Registrational trials for these two drugs are expected to begin in 2H19. We believe these trials will drive more interest in ArQule and push the stock higher. For the other two products, ARQ 751 and derazantinib, we consider them free call options. Management projects cash and marketable securities on the balance sheet will total approximately $160M at the end of 2019, which is forecast to fund operating expenses into 2022. Targeting treatment resistance in B-cell malignancies." (9/16/2019)

Has ArQule been receiving favorable news coverage?

News articles about ARQL stock have trended very positive recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ArQule earned a coverage optimism score of 3.4 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for ArQule.

Are investors shorting ArQule?

ArQule saw a decline in short interest during the month of December. As of December 13th, there was short interest totalling 13,850,000 shares, a decline of 27.4% from the November 28th total of 19,070,000 shares. Based on an average trading volume of 3,990,000 shares, the short-interest ratio is currently 3.5 days. Approximately 12.5% of the shares of the company are short sold. View ArQule's Current Options Chain.

Who are some of ArQule's key competitors?

What other stocks do shareholders of ArQule own?

Who are ArQule's key executives?

ArQule's management team includes the folowing people:
  • Mr. Paolo Pucci, CEO & Director (Age 58)
  • Mr. Peter S. Lawrence J.D., Pres, COO, Gen. Counsel & Sec. (Age 56)
  • Dr. Brian Schwartz, Chief Medical Officer & Sr. VP (Age 57)
  • Mr. Robert J. Weiskopf, CFO, Sr. VP, Principal Accounting Officer & Treasurer (Age 68)
  • Dr. Marc Schegerin M.D., CFO, Head of Strategy & Treasurer

Who are ArQule's major shareholders?

ArQule's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Syquant Capital Sas (0.51%), FNY Investment Advisers LLC (0.38%), Alpine Global Management LLC (0.07%), Calamos Advisors LLC (0.04%) and Curbstone Financial Management Corp (0.03%). Company insiders that own ArQule stock include Paolo Pucci, Patrick J Zenner, Ran Nussbaum, Ronald M Lindsay and Value Fund L P Biotechnology. View Institutional Ownership Trends for ArQule.

Which institutional investors are selling ArQule stock?

ARQL stock was sold by a variety of institutional investors in the last quarter, including Curbstone Financial Management Corp. View Insider Buying and Selling for ArQule.

Which institutional investors are buying ArQule stock?

ARQL stock was bought by a variety of institutional investors in the last quarter, including Syquant Capital Sas, FNY Investment Advisers LLC, Alpine Global Management LLC and Calamos Advisors LLC. Company insiders that have bought ArQule stock in the last two years include Paolo Pucci, Patrick J Zenner, Ran Nussbaum and Ronald M Lindsay. View Insider Buying and Selling for ArQule.

How do I buy shares of ArQule?

Shares of ARQL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ArQule's stock price today?

One share of ARQL stock can currently be purchased for approximately $20.00.

How big of a company is ArQule?

ArQule has a market capitalization of $2.42 billion and generates $25.76 million in revenue each year. The biotechnology company earns $-15,480,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. ArQule employs 36 workers across the globe.View Additional Information About ArQule.

What is ArQule's official website?

The official website for ArQule is http://www.arqule.com/.

How can I contact ArQule?

ArQule's mailing address is ONE WALL STREET, BURLINGTON MA, 01803. The biotechnology company can be reached via phone at 781-994-0300 or via email at [email protected]


MarketBeat Community Rating for ArQule (NASDAQ ARQL)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  417 (Vote Outperform)
Underperform Votes:  370 (Vote Underperform)
Total Votes:  787
MarketBeat's community ratings are surveys of what our community members think about ArQule and other stocks. Vote "Outperform" if you believe ARQL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARQL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2020 by MarketBeat.com Staff

Featured Article: Why Invest in Dividend Achievers?
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel